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We  here  present  an  improved  version  of  AutoGrow  (version  3.0),  an evolutionary  algorithm  that  works
in  conjunction  with  existing  open-source  software  to  automatically  optimize  candidate  ligands  for pre-
dicted  binding  afﬁnity  and  other druglike  properties.  Though  no substitute  for  the  medicinal  chemist,
AutoGrow  3.0,  unlike  its predecessors,  attempts  to introduce  some  chemical  intuition  into  the  auto-
mated  optimization  process.  AutoGrow  3.0  uses  the  rules  of click  chemistry  to guide  optimization,  greatly
enhancing  synthesizability.  Additionally,  the program  discards  any growing  ligand  whose  physical  and
chemical  properties  are  not  druglike.  By carefully  crafting  chemically  feasible  druglike  molecules,  we
hope  that  AutoGrow  3.0  will  help  supplement  the  chemist’s  efforts.utogrow
omputational chemistry
To demonstrate  the  utility  of  the  program,  we use  AutoGrow  3.0  to generate  predicted  inhibitors  of
three  important  drug  targets:  Trypanosoma  brucei  RNA  editing  ligase  1,  peroxisome  proliferator-activated
receptor  , and  dihydrofolate  reductase.  In all  cases,  AutoGrow  generates  druglike  molecules  with  high
predicted  binding  afﬁnities.
AutoGrow 3.0  is available  free  of  charge  (http://autogrow.ucsd.edu) under  the  terms  of  the GNU  General
en  te
 201
Public  License  and  has be
©
. Introduction
Ligand identiﬁcation and optimization are challenging tasks. In
ecent years, computational algorithms have played increasingly
rominent roles in assisting the medicinal chemist. Driven by the
xponential growth of computer power and the ever expanding
umber of experimentally derived, atomistic structures of recep-
ors and ligand–receptor complexes [1], these programs have been
pplied at almost every stage of the drug-discovery process. Com-
utational algorithms have assisted in the development of many
rugs, including dorzolamide, zanamivir, oseltamivir, nelﬁnavir,
altegravir, aliskiren, and boceprevir [2–4].
Despite advances in computer-aided drug discovery, the pro-
esses of ligand identiﬁcation and optimization are still largely
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f  California San Diego, 9500 Gilman Drive, Mail Code 0365, La Jolla, CA 92093-0365,
nited  States. Tel.: +1 858 822 0169; fax: +1 858 534 4974.
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093-3263 © 2013 The Authors. Published by Elsevier Inc. 
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3 The Authors. Published by Elsevier Inc. 
medicinal-chemist driven. While computers lack the insight and
intuition that chemists have, recent efforts have sought to improve
automation; the AutoGrow algorithm [5], among others [6–14],
has been developed to aid the identiﬁcation and optimization of
predicted ligands. The initial version, released in 2009, uses an
evolutionary algorithm in conjunction with existing docking soft-
ware to add interacting moieties to models of known inhibitors in
order to optimize their predicted binding afﬁnities. At the time of
its initial release, the main advantage of the program was its degree
of automation; beyond the initial setup of fragment libraries and
docking parameters, no user interaction is required until the ﬁnal
compounds are presented for evaluation.
However, in the absence of the chemist’s insight, AutoGrow
versions 1.0 and 2.0 often produce compounds that are neither
druglike nor easily synthesizable. These programs are useful for
providing chemists with insights into possible ligand–receptor
interactions, but if a compound cannot be synthesized and/or lacks
the necessary physical properties characteristic of approved drugs
[15,16], clinical success is unlikely.
Open access under CC BY-NC-ND license.In the current paper, we present AutoGrow 3.0, an improved
algorithm that attempts to introduce some chemical intuition
into the automated identiﬁcation/optimization process. Though no
substitute for the medicinal chemist, AutoGrow 3.0 can produce
e.
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hemically synthesizable, druglike molecules that may  supplement
he chemist’s efforts. Version 3.0 is signiﬁcantly improved over pre-
ious versions. Additionally, as the new implementation is written
n python rather than java, editing and expanding the code is easier
han ever.
AutoGrow 3.0 is dependent on several other free software pack-
ges, including MGLTools [17], Open Babel [18], AutoDock Vina
19], and NumPy/SciPy [20]. We  are hopeful that AutoGrow 3.0 will
e even more useful to the drug-design community than previous
mplementations. A copy can be downloaded free of charge from
ttp://autogrow.ucsd.edu/.
. Design and implementation
.1.  The AutoGrow 3.0 algorithm
As an evolutionary algorithm, AutoGrow 3.0 deals not with a
ingle ligand, but with populations of ligands. These populations
re divided into “generations.” Each generation is subject to three
perators, called mutation, crossover, and selection [5].
To  derive a novel compound via mutation, AutoGrow 3.0 ﬁrst
andomly selects one of the many click-chemistry reactions pro-
rammed into AutoClickChem [21]. A fragment that can participate
n this reaction is then selected at random from a user-speciﬁed
atabase and added to the known or suspected ligands by simulat-
ng the reaction in silico.
AutoClickChem  performs two kinds of virtual reactions. Modiﬁ-
ation reactions involve replacing certain moieties with chemically
eactive groups. For example, a halide atom can be replaced with an
zide group. In contrast, joining reactions involve combining two
istinct molecular models into one via simulated click-chemistry
eactions. For example, a molecule containing an azide group can
e joined to a molecule containing an alkyne group via a simu-
ated azide-alkyne Huisgen cycloaddition. AutoGrow 3.0 allows the
ser to specify whether “mutant” ligands should be derived using
oth modiﬁcation and joining reactions, or if joining reactions alone
hould be permitted.
The  AutoGrow 3.0 crossover operator is based on the LigMerge
lgorithm [22]. First, two “parent” molecules are aligned by super-
mposing the maximum (largest) substructure common to both.
ovel compounds are then generated by systematically mixing and
atching the distinct fragments attached to the respective aligned
ubstructures. In this way, “child” molecules can be generated that
re topologically similar to but nevertheless distinct from their two
parents.”
Once a generation of compounds has been created using the
utation and crossover operators, the selection operator is used to
dentify the ligands that are the most “ﬁt.” A number of criteria are
sed in selecting the top ligands. First, each ligand is evaluated for
ruglike properties using Open Babel [18] and python deﬁnitions
uilt with the pymolecule framework [21]. Compounds that are not
ruglike are discarded. The user can select whether generated com-
ounds must satisfy Lipinski’s Rule of Fives [15] with no violations,
ipinski’s Rule of Fives with at most one violation, or the criteria
escribed by Ghose et al. [16].
The user can also instruct AutoGrow to discard any compounds
hat do not contain speciﬁc, key moieties. For example, suppose
revious research has identiﬁed ten inhibitors that all contain a
ingle carboxylate group. As the carboxylate group may  be critical
or binding, the user may  wish to use AutoGrow to generate novel
ompounds from these ten that preserve this key moiety. How-
ver, AutoClickChem considers carboxylate groups to be reactive
nd tends to convert them into esters, amides, etc. Additionally,
igMerge could potentially generate compounds that do not con-
ain the carboxylate group. To preserve this key moiety, the user canhics and Modelling 44 (2013) 104–112 105
“mark” the two  oxygen atoms of the carboxylate group by editing
the PDB ﬁles of the ten known inhibitors and in every case append-
ing an exclamation point to the atom names of the two  carboxylate
oxygen atoms. AutoGrow can then be instructed to discard all gen-
erated compounds that do not contain at least two  marked atoms,
thus preserving the key moiety.
Finally, those ligands that remain are subsequently docked into
the receptor of interest using AutoDock Vina [19]. Optionally, the
docked poses can be reevaluated with NNScore 1.0 [23] or NNScore
2.0 [24]. The best-scoring ligands are then selected to be the
founders of the next generation. The compounds of this new gener-
ation are again created via mutation and crossover operators, this
time applied to the best ligands of the previous generation, and the
process begins anew, repeating until the user-speciﬁed number of
generations has been completed.
2.2. Fragment libraries
The  mutation (AutoClickChem) operator draws upon a user-
speciﬁed library of molecular fragments. In the absence of a
user-generated fragment library, one of the default libraries that
ship with AutoGrow 3.0 can be used. These default libraries were
generated by performing sub-structure searches of the compounds
in the ZINC database [25] to identify fragments that could poten-
tially participate in any of the many reactions of click chemistry
[21]. Molecules containing acid anhydride, acyl halide, alcohol,
thiol, alkene, alkyne, amine, azide, carbonochloridate, carboxylate,
epoxide, ester, halide, isocyanate, isothiocyanate, sulfonylazide,
and thio acid moieties were included. The structures of these com-
pounds were optimized using Schrodinger’s LigPrep program in
conjunction with the OPLS 2005 forceﬁeld [26,27]. The LigPrep
models were then ﬁltered according to molecular weight and cat-
egorized by the speciﬁc reactive moiety identiﬁed. Libraries of
fragments with molecular weights less than 150, 200, and 250 Da,
containing 2264, 8772, and 21,010 fragments, respectively, are pro-
vided with the program.
2.3.  AutoGrow runs
To  demonstrate the utility of the AutoGrow algorithm, crystal
structures of RNA editing ligase 1 (REL1), peroxisome proliferator-
activated receptor  (PPAR), and dihydrofolate reductase (DHFR)
were obtained form the Protein Data Bank (PDB) [1] (PDB IDs:
1XDN [28], 1FM9 [29], and 3DFR [30], respectively). In all three
cases, crystallographic water molecules and co-crystallized lig-
ands were removed. We  note, however, that AutoGrow does not
require that water molecules be removed, and in some cases these
molecules may  in fact mediate important ligand–receptor inter-
actions. Hydrogen atoms were subsequently added to the protein
using PDB2PQR [31,32]. In the case of DHFR, the NDP cofactor was
retained, with hydrogen atoms assigned according to those present
in the DUD database [33].
For  REL1, AutoGrow created 20 mutants per generation
and advanced the top ten to the subsequent generation.
AutoClickChem, serving as the mutation operator, performed both
modiﬁcation and joining click-chemistry reactions. No crossover
operations were permitted. For PPAR, AutoGrow generated ten
mutants and ﬁve crossovers for each generation, advancing the top
ﬁve to the subsequent generation. For DHFR, AutoGrow generated
ten mutants and ten crossovers for each generation, advancing the
top ﬁfteen to the subsequent generation.
In all three cases, AutoDock Vina [19] was used for docking
and scoring. Docking boxes centered on the REL1, PPAR,
and DHFR actives sites measured 30 A˚ × 30 A˚ × 20 A˚,
40.912 A˚ × 44.262 A˚ × 46.769 A˚, and 42.851 A˚ × 44.835 A˚ × 44.012 A˚,
respectively. In all three cases, compounds were ﬁltered according
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o Lipinski’s Rule of Fives (no violations allowed), and fragment
ddition drew upon the default AutoGrow 3.0 fragment library of
ompounds with molecular weights less than 250 Da.
. Results and discussion
A  number of ligand-optimization schemes based on evolution-
ry algorithms have been proposed [34]. Among these, AutoGrow
5] has been used to provide insight into the design of inﬂuenza
euraminidase [35,36] and Trypanosoma brucei RNA editing ligase
 inhibitors [37]. AutoGrow 3.0 includes signiﬁcant improvements
ver previous versions that will make the algorithm even more
seful for drug discovery.
.1.  AutoGrow improvements
The  new AutoGrow mutation operator helps ensure chemi-
al synthesizability. In versions 1.0 and 2.0, the replacement of a
ingle hydrogen atom with a molecular fragment chosen at ran-
om from a database constitutes a “mutation.” While useful as
 means of identifying potential interactions and fragments that
ight aid drug design and optimization, the compounds generated
y AutoGrow 1.0 and 2.0 are not necessarily druglike or synthesiz-
ble. The mutation operator simply replaces hydrogen atoms with
olecular fragments, without regard for the chemistry required to
ctually generate the compounds ex silico. AutoGrow 3.0 addresses
hese deﬁcits by adding fragments according to the rules of click
hemistry [21]. Consequently, the resulting products can be easily
ynthesized for subsequent experimental testing.
The AutoGrow crossover operator, which generates novel com-
ounds by mixing and matching moieties from two “parents,” is
lso much improved. Based on LigMerge [22], this enhanced opera-
or allows for crossovers between even structurally distinct ligands.
se of the crossover operator is likely to increase the diversity
resent in each AutoGrow generation, permitting the algorithm
o ultimately generate more potent predicted ligands. However,
igMerge can in principle generate compounds that are not easily
ynthesizable. The user must decide if the potential for enhanced
otency justiﬁes the risk of generating chemically intractable com-
ounds. If users are particularly concerned about synthesizability,
he crossover operator can be easily deactivated, and predicted
igands can be generated using the mutation operator alone. We
o note, however, that LigMerge-generated compounds are still
ore likely to be synthesizable than compounds derived using
he crossover operators of previous AutoGrow versions because
he LigMerge compounds are themselves derived from presum-
bly synthesizable molecules (e.g. known inhibitors) and so contain
ruglike substructures.
Signiﬁcant improvements have also been made to the selec-
ion operator. Previous versions of AutoGrow ignored the druglike
roperties of the ligands generated; in the current implemen-
ation, compounds that do not meet key criteria are discarded
mmediately. Ligand creation proceeds until the current generation
ontains the required number of druglike mutants and crossovers.
peciﬁcally, ligands are evaluated using the criteria presented by
ipinski et al. [15] and Ghose et al. [16]. Lipinski’s Rule of Fives
tates that an orally active, druglike molecule typically has no
ore than one violation of the following criteria: the number of
ydrogen-bond donors is less than or equal to ﬁve, the number of
ydrogen-bond acceptors is less than or equal to ten, the molec-
lar weight is less than 500 Da, and the octanol–water partition
oefﬁcient (logP value) is less than or equal to ﬁve. Similarly, Ghose
t al. suggest that druglike molecules generally satisfy ﬁve criteria:
he logP is between −0.4 and 5, the molar refractivity is between
0 and 130, the molecular weight is between 160 and 500 Da, thehics and Modelling 44 (2013) 104–112
number  of atoms is between 20 and 70, and the polar surface area
is less than or equal to 140 A˚2. In AutoGrow 3.0, the user selects
whether generated compounds must satisfy Lipinski’s Rule of Fives
with no violations, Lipinski’s Rule of Fives with at most one viola-
tion (as originally proposed), or the criteria described by Ghose and
coworkers.
Like previous implementations, AutoGrow 3.0 also considers
docking scores when identifying ﬁt ligands. Each ligand is docked
into the receptor of interest using AutoDock Vina [19]. Auto-
Grow 3.0 adds the option to reevaluate the docked poses with
NNScore 1.0 [23] or NNScore 2.0 [24], neural-network-based sco-
ring functions that for some systems are more accurate than the
Vina scoring function [24,38]. As the performance of different sco-
ring functions is highly dependent on the protein receptor being
studied, we  recommend using known inhibitors (positive con-
trols) to validate a given scoring function prior to starting an
AutoGrow run.
3.2.  Examples of usage
AutoGrow  3.0 can generate entirely novel predicted inhibitors
ex nihilo from very basic starting structures. Alternatively, it
can optimize existing inhibitors in order to improve the pre-
dicted binding afﬁnity. To demonstrate these two  techniques,
we provide three examples of use. First, we generate pre-
dicted inhibitors of T. brucei RNA editing ligase 1 (REL1) by
building entirely novel molecules from very basic brominated ben-
zenes, without regard for the structures of known inhibitors. We
similarly generate predicted inhibitors of peroxisome proliferator-
activated receptor  (PPAR) from a small library of slightly
more diverse starting molecules. Finally, we demonstrate ligand
optimization by generating predicted inhibitors of dihydrofolate
reductase (DHFR) using known inhibitors as the starting struc-
tures.
3.3. Example: inhibitors of T. brucei RNA editing ligase 1
To  demonstrate the utility of AutoGrow 3.0 in creating novel lig-
ands ex nihilo, we  ﬁrst designed predicted inhibitors of RNA editing
ligase 1 (REL1) from T. brucei, the etiological agent of African sleep-
ing sickness. As TbREL1 is critical for the survival of the T. brucei
parasite [39], it has been the target of several drug-discovery efforts
in recent years [40–43].
AutoGrow  created the initial generation of compounds from 12
simple halogenated benzenes: bromobenzene, perbromobenzene,
pentabromobenzene, and all possible dibromobenzenes, tribro-
mobenzenes, and tetrabromobenzenes. Benzene rings are common
drug moieties, and AutoClickChem can convert the attached bro-
mide atoms into other reactive groups, particularly azides. Running
on a workstation with eight cores, AutoGrow iterated through 17
generations in 2 days, 10 h. In all, AutoGrow generated 89 syn-
thesizable compounds with docking scores equal to or better than
−10 kcal/mol.
Among  the top compounds of the 17th generation, com-
pound 1 (Fig. 1) seemed promising. Examination revealed that
this compound was produced by multiple AutoClickChem reac-
tions, including two  reactions that led to fragment additions.
The predicted binding pose of compound 1 (Fig. 2A) is rem-
iniscent of the known binding pose of ATP [28], the natural
substrate, in that aromatic rings are buried deep within the
adenine-binding pocket where they form -stacking interactions
with F209. Additionally, compound 1 is predicted to form two
hydrogen bonds with the receptor residues H89 and R288 and
to participate in possible cation- interactions with R111 at the
periphery.
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oFig. 1. The evolutionary steps taken
Fig. 3 shows the average Vina score of the top-ﬁve ranked
ompounds of each generation. After 17 generations, the best-
coring AutoGrow compound had a predicted binding afﬁnity of
12.7 kcal/mol, comparable to the docking scores of known TbREL1
nhibitors. This inhibitor was ultimately derived from a tetrabro-
obenzene fragment whose predicted TbREL1 binding afﬁnity was
nly −4.2 kcal/mol, demonstrating signiﬁcant optimization (Fig. 1).erate a predicted TbREL1 inhibitor.
3.4. Example: inhibitors of peroxisome proliferator-activated
receptor As  an additional example of creating predicted ligands ex nihilo,
we next applied AutoGrow to peroxisome proliferator-activated
receptor  (PPAR), the molecular target of several FDA-approved
treatments for diabetes.
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big. 2. The predicted binding poses of top AutoGrow-generated compounds. (A)
bREL1; (B) PPAR; (C) DHFR.
AutoGrow created the ﬁrst generation of compounds from
 series of small bromine-containing fragments that are some-
hat more diverse than the benzene derivatives used in the
EL1 runs: 2-phenylacetyl bromide, (bromomethyl)benzene, (R)-
romo(phenyl)methanol, benzoyl bromide, benzimidoyl bromide,Fig. 3. The average Vina score of the top-ﬁve ranked compounds of each generation.
N-bromobenzenaminium, benzoyl bromide, phenyl carbonobro-
midate, and N-bromoaniline. As before, brominated compounds
were selected because AutoClickChem can easily convert them into
other reactive groups, particularly azides.
Running on 8 cores, AutoGrow iterated through 6 generations in
4 h and 6 min. The program was manually terminated after spend-
ing nearly 24 h trying to generate the 15 ligands of the seventh
generation. Thus we see that it is possible for AutoGrow to take
evolutionary paths that are ultimately cul-de-sacs; in some situa-
tions, AutoGrow may  not be able to generate a sufﬁcient number of
novel ligands to complete a generation. This is especially true when
many constraints are placed on ligand growth (e.g. too few mutant
or crossover products per generation, too few initial ligands from
which to derive the ligands of the ﬁrst generation, too strict criteria
for determining whether a compound is druglike, etc.).
If  the user is reluctant to manually monitor the AutoGrow output
for this cul-de-sac scenario, the program can also be instructed to
automatically terminate if any generation takes more than a user-
speciﬁed number of seconds. Additionally, if an evolutionary cul-
de-sac occurs early in an AutoGrow run, one need only restart the
program. AutoGrow 3.0, like its predecessors, is non-deterministic.
Each run produces different potential ligands by following different
evolutionary paths.
Compound  2 (Fig. 4) of the sixth generation had the best
predicted binding energy while maintaining druglike properties.
Examination revealed that this compound was produced by multi-
ple AutoClickChem and LigMerge operations. While one should not
place too much conﬁdence in a docked pose, it is nevertheless note-
worthy that the predicted pose of compound 2 is credible (Fig. 2B).
Speciﬁcally, aside from having excellent shape complementarity,
the compound is also predicted to form a hydrogen bond with R288
and a -stacking interaction with F287.
Fig. 3 shows the average Vina score of the top-ﬁve ranked
compounds of each generation. After 6 generations, the best-
scoring AutoGrow compound had a predicted binding afﬁnity
of −10.1 kcal/mol. This inhibitor was ultimately derived from 2-
phenylacetyl bromide, whose predicted PPAR binding afﬁnity was
only −7.0 kcal/mol, demonstrating signiﬁcant optimization. In all,
AutoGrow generated 2 easily synthesizable compounds with dock-
ing scores equal to or better than −10 kcal/mol.
3.5.  Example: inhibitors of dihydrofolate reductase
Having shown that AutoGrow 3.0 can be used to generate pre-
dicted ligands ex nihilo, we  next used AutoGrow to optimize known
ligands of dihydrofolate reductase (DHFR), the molecular target of
several anti-bacterial and anti-cancer agents [44,45].
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Fig. 4. The evolutionary steps taken to generate a predicted PPAR inhibitor.
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cThe initial AutoGrow generation was created from 66 models of
nown DHFR inhibitors. These models were derived from the top
0 DHFR inhibitors with the lowest IC50 values listed in the Bind-
ngDB database [46] using Schrodinger’s LigPrep program. Each
f these ligands contained a pyrimidine-2,4-diamine substructure
hat binds deep in the DHFR folate-binding site. As this moiety is
ikely critical to binding, AutoGrow was instructed to only consider
ompounds that preserved it.Running  on a workstation with eight cores, AutoGrow iterated
through 9 generations in 6 h, 50 min. Among the top compounds
of the 9th generation, compound 3 (Fig. 5) had the highest Vina
score. Compound 3 was  produced by multiple AutoClickChem
reactions and LigMerge crossovers. The predicted binding pose
(Fig. 2C) is similar to that of known inhibitors in that it positions
the pyrimidine-2,4-diamine substructure deep within the folate-
binding pocket [30]. Aside from hydrophobic contacts, compound
110 J.D. Durrant et al. / Journal of Molecular Graphics and Modelling 44 (2013) 104–112
Fig. 5. The evolutionary steps taken to generate a predicted DHFR inhibitor. A subtle gray background is included to facilitate visualization. The evolutionary paths depicted
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−re  admittedly convoluted; the primary purpose of this ﬁgure is to demonstrate the c
etails.
 is predicted to form a hydrogen bond with the D26 carboxylate
ide chain and two T-shaped aromatic interactions with F30 and
49 [47].
Fig.  3 shows the average Vina score of the top-ﬁve ranked
ompounds of each generation. After 9 generations, the best-
coring AutoGrow compound had a predicted binding afﬁnity of
11.5 kcal/mol. This compound was ultimately derived from sevenexity of the AutoGrow evolutionary process rather than to provide speciﬁc chemical
known  DHFR inhibitors with docking scores ranging from −8.2 to
−10.1 kcal/mol. This improvement in predicted binding afﬁnity is
more modest than that of the two  previous examples, as expected
given that the original compounds were known inhibitors that had
presumably already been subject to optimization.
In all, AutoGrow generated 18 easily synthesizable compounds
with docking scores equal to or better than −10 kcal/mol.
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. Conclusions/availability
In the current work, we built upon our previous experience
ith virtual-screening and compound-library design to create a
ew version of AutoGrow (3.0) that is signiﬁcantly improved
ver previous releases. While no substitute for the medicinal
hemist, AutoGrow 3.0 does incorporate some chemical intu-
tion into its ligand-growing strategy. Unlike previous versions
f AutoGrow, version 3.0 rejects any compounds that are not
ruglike. Additionally, the program now adds fragments to core
caffolds by simulating the reactions of click chemistry rather
han merely replacing hydrogen atoms with molecular fragments
ithout regard for synthesizability. AutoGrow 3.0 has been specif-
cally tested on Ubuntu 12.10 with python 2.7.3, NumPy 1.6.2,
ciPy 0.10.1, MGLTools 1.5.6rc3, Open Babel 2.3.2, and AutoDock
ina 1.1.2; Scientiﬁc Linux 6.2 with python 2.6.6, NumPy 1.6.2,
ciPy 0.11.0, MGLTools 1.5.4, Open Babel 2.3.1, and AutoDock Vina
.1.2; and Mac  OS X 10.8.1 with python 2.7.2, NumPy 1.6.1, SciPy
.12.0dev, MGLTools 1.5.6, Open Babel 2.3.1, and AutoDock Vina
.1.2. We  are hopeful that AutoGrow 3.0 will be a helpful tool for
he drug-discovery community.
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